VISN
CommScope Holding Company, Inc.NASDAQTECHNOLOGYCOMMUNICATION EQUIPMENT
Key Statistics
Market Cap
$4.20B
P/E Ratio
16.78
EPS
$1.11
Beta
2.38
52W High
$20.55
52W Low
$2.94
50-Day MA
$18.19
200-Day MA
$15.81
Dividend Yield
—
Profit Margin
118.20%
Forward P/E
3.72
PEG Ratio
2.94
About CommScope Holding Company, Inc.
Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.
Fundamentals
| Revenue (TTM) | $1.93B |
| Gross Profit (TTM) | $955.90M |
| EBITDA | $379.00M |
| Operating Margin | 29.10% |
| Return on Equity | 0.00% |
| Return on Assets | 0.70% |
| Revenue/Share (TTM) | $8.80 |
| Book Value | $-4.50 |
| Price-to-Book | 30.36 |
| Price-to-Sales (TTM) | 2.17 |
| EV/Revenue | 6.22 |
| EV/EBITDA | 38.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 50.60% |
| Shares Outstanding | $225.46M |
| Float | $217.39M |
| % Insiders | 3.37% |
| % Institutions | 90.80% |
Analyst Ratings
Consensus ($23.12 target)
2
Buy3
HoldData last updated: 4/9/2026